Document:

EXHIBIT 10.4

                         AMENDMENT TO LICENSE AGREEMENT

      This Amendment to License Agreement ("Amendment") is entered into as of
September 5, 2000, by and between BUKWANG PHARM. IND. CO., LTD., with its
principal offices at 398-01, Daebang-Dong, Dongjak-Ku, Seoul 156-020, Korea
("Bukwang") and TRIANGLE PHARMACEUTICALS, INC., with its principal offices
located at 4 University Place, 4611 University Drive, Durham, North Carolina
27707 ("Triangle") and amends certain terms of that certain License Agreement,
dated as of February 27, 1998, between Bukwang and Triangle, as amended April 1,
1999 (the "Agreement"). Capitalized terms not defined herein shall have the
meanings given them in the Agreement.

                                    RECITALS

      A. Bukwang and Triangle have previously entered into the Agreement,
pursuant to which Bukwang has licensed certain patent rights and know-how to
Triangle relating to a compound known as L-FMAU.

      B. Triangle has certain obligations to make a milestone payment upon the
*** and upon the *** .

      C. As part of its diligence efforts in respect of L-FMAU, Triangle is
required to use its best efforts to file an NDA for a Licensed Product with the
FDA *** .

      D. Bukwang and Triangle desire to amend and clarify certain terms of the

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
<PAGE>

Agreement relating to such milestone payment and due diligence time limits.

      NOW, THEREFORE, for good and valuable consideration, Triangle and Bukwang
hereby agree as follows:

      1.    Amendments. The Agreement is hereby amended as follows:

            (a)   Section 1.15. Delete Section 1.15 and replace it with the
                  following: "IND" shall mean a U.S. or Canadian Investigational
                  New Drug Application or its equivalent in either country."

            (b)   Section 1.22. Delete Section 1.22 and replace it with the
                  following: "`NDA' shall mean a New Drug Application or its
                  equivalent filed in the U.S., China or, in the case of Europe,
                  with the European Agency for the Evaluation of Medicinal
                  Products."

            (c)   Subsection 6.2(a)(i). Delete Subsection 6.2(a)(i) and replace
                  it as follows: "(i) files what it reasonably believes to be a
                  complete NDA for a Licensed Product for HBV within *** after
                  the Effective Date; provided, however, said *** period shall
                  be subject to up to *** extensions of *** , at Triangle's
                  election, by payment to Bukwang of a sum of $ *** for each ***
                  extensions and $ *** for each *** extensions."

      2.    General Terms. The Agreement, as amended by this Amendment,
            constitutes the entire agreement between Bukwang and Triangle or
            regarding the subject matters contained therein and herein. In the
            event of any conflict between the provisions of the Agreement and
            this

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
<PAGE>

            Amendment, the provisions of this Amendment shall govern and
            control. This Amendment shall be governed by, and construed in
            accordance with, the laws of the State of Georgia without regard to
            its conflicts of laws principles. This Amendment may be executed in
            any number of counterparts, each of which shall be deemed an
            original and all of which shall constitute one and the same
            instrument. If any provision of this Amendment is for any reason
            held to be ineffective, unenforceable or illegal, such condition
            shall not affect the validity or enforceability of any of the
            remaining portions hereof; provided, further, that the parties shall
            negotiate in good faith to replace any ineffective, unenforceable or
            illegal provision with an effective replacement as soon as is
            practical.

      IN WITNESS WHEREOF, Bukwang and Triangle have each executed this Amendment
through an authorized officer as of the date written below.

                                    BUKWANG PHARM. IND. CO., LTD.

                                    By:   /s/ Sung-Koo Lee
                                          ------------------------------
                                    Its:  Managing Director
                                          ------------------------------
                                    Date: September 21, 2000
                                          ------------------------------

                                    TRIANGLE PHARMACEUTICALS, INC.

                                    By:   /s/ Chris A. Rallis
                                          ------------------------------
                                    Its:  President and COO
                                          ------------------------------
                                    Date: September 5, 2000
                                          ------------------------------RESIGNATION AGREEMENT

      This Agreement (the "Agreement") is entered into as of the 22nd day of
September 2000 by and between Dispatch Management Services Corp., a Delaware
corporation, and its affiliates ("DMS" or the "Company") and H. Steve Swink
("Mr. Swink").

      Whereas, DMS and Mr. Swink entered into an employment agreement dated
February 1, 1999, as amended on March 30, 1999 (the "Employment Agreement");

      Whereas, DMS and Mr. Swink have agreed to terminate the Employment
Agreement effective September 22, 2000 according to the terms of this Agreement;
and

      Whereas, Mr. Swink has tendered his resignation from his positions as both
a director and Chief Executive Officer of DMS;

      Now, therefore, in consideration of the premises and the mutual promises
set forth in this Agreement, the parties agree as follows:

      1. Compensation Through to end of Employment Contract Period

            (a) Cash Compensation: From this date through January 31, 2001 (the
      "Employment Period"), DMS shall continue to pay to Mr. Swink, for services
      as, and subject to performance as, an employee upon request of DMS or any
      of its representatives, an annualized salary at a rate of $300,000.00 per
      year. Such payments shall be made in equal bi-weekly installments, or such
      other installments as may be mutually agreed upon between the parties,
      subject to deduction and withholding for taxes, employee benefits and/or
      as otherwise required by law or provided by agreement of the parties.

            (b) Benefits: During the Employment Period, DMS shall continue to
      provide Mr. Swink with all health, insurance and other employee benefits
      customarily provided to employees of the company.

      2. Stock Options:

      Upon termination of the Employment Period, Mr. Swink's stock options shall
      become exercisable as follows:

            (a) The stock options exercisable for 250,000 shares of the
      Company's common stock granted pursuant to Mr. Swink's employment
      agreement, which have vested, shall remain exercisable through February
      22, 2009, as is consistent with the terms of Mr. Swink's employment
      agreement. Mr. Swink's Stock Option Agreements dated February 22, 1999
      shall be appropriately revised to be consistent with the intent of the
      parties to Mr. Swink's employment agreement.
<PAGE>

            (b) All other stock options exercisable for shares of the Company's
      common stock granted to Mr. Swink shall vest and become exercisable
      pursuant to the terms of their respective Stock Option Agreements.

      3. Future Advisory Work.

From February 1, 2001 through September 31, 2001 (the "Advisory Period"), Mr.
Swink shall fully cooperate with representatives of DMS and shall make himself
reasonably available to answer questions and perform certain advisory services.
At the request of DMS, Mr. Swink shall make himself available, at mutually
agreeable times and in a mutually agreeable manner, to assist with questions
concerning historical information relating to the Company. DMS agrees to pay Mr.
Swink consulting fees in an annualized amount equal to $300,000.00 per year,
payable in equal bi-weekly installments through the end of the Advisory Period
subject to Mr. Swink's performance of such advisory services.

      4. Resignation

DMS acknowledges that Mr. Swink has tendered his resignation from his positions
as both a member of the board of directors and as Chief Executive Officer of DMS
effective September 22, 2000.

      5. Mutual General Releases

Mr. Swink hereby releases, acquits, and forever discharges any and all claims
and demands of whatever kind or character, indirect or direct, that he may have
or assert against DMS and/or its directors, officers, employees or agents. This
general release includes, but is not limited to, any claim or demand based on
any State, Federal or local statutory or common law that applies or is asserted
to apply directly or indirectly to any relationship which Mr. Swink may have had
with DMS, including, without limitation, claims arising out of any, or related
to any claims for, breach of contract, wrongful discharge, unlawful
discrimination, violation of the public policy of the United States or the State
of New York, violations of Title VII of the Civil Rights Act of 1964, the Age
Discrimination in Employment Act of 1967, the Employee Retirement Income
Security Act of 1974, the Americans with Disabilities Act of 1990, the Family
and Medical Leave Act, the Fair Labor Law, the New York Executive Law, as
amended, including the New York Human Rights Law and the New York Labor Law, or
any other State or Federal Statute arising out of his relationship, or the
termination of his relationship with DMS, but expressly excluding claims
directly arising out of or related to a breach of the obligations of DMS under
this Agreement.

DMS and its directors and officers hereby release, acquit and discharge any and
all claims and demands of whatever kind or character, whether direct or
indirect, that it may have or assert against Mr. Swink. This general release
expressly excludes claims directly arising or related to a breach of the
obligations of Mr. Swink under this Agreement.

      6. Confidentiality of this Agreement

                                       2
<PAGE>

In consideration of the obligations of DMS under this Agreement, Mr. Swink
agrees that the terms of this Agreement shall be and remain confidential, and
shall not be disclosed by him to any party other than family members, attorneys
or accountants (provided that such persons agree to keep such information
confidential), and except as may be required by law.

      7. Non-disparagement

Mr. Swink agrees to refrain from making disparaging, negative or other similar
remarks concerning DMS, its directors, officers, employees, agents or other
related persons to any third party, except to the extent that Mr. Swink is
required to make such remarks (a) by applicable law or regulation or judicial or
regulatory process or (b) in or in connection with any pending or threatened
litigation relating to this Agreement or any transaction contemplated hereby or
thereby. In view of the difficulty of determining the amount of damages that may
result to DMS from the breach of the provision of this Section 6, it is the
intent of the parties hereto that, in addition to monetary damages, DMS shall
have the right to prevent any such breach in equity or otherwise, including,
without limitation, prevention by means of injunctive relief, and to withhold
payment of any compensation or fees required by Sections 1 or 2 hereof in the
event of any such breach.

      8. Governing Law

This Agreement shall be interpreted and applied under the laws of the State of
New York.

      9. Notices

Any notice or communication required or permitted hereunder shall be in writing
and either delivered personally or telecopied or sent by overnight courier, or
by certified or registered mail, postage prepaid, and shall be deemed to be
given, dated and received when so delivered personally or by courier or
telecopied, or, if mailed, three business days after the date of mailing to the
following respective address or telecopy number, or to such other address or
addresses as such person may subsequently designate by written notice given
hereunder:

if to DMS, to:
Mr. Bruce Morgan
President
Dispatch Management Services Corp.
1981 Marcus Avenue, C131
Lake Success, New York 11042

if to Mr. Swink to:
Mr. H. Steve Swink
[        ]

                                       3
<PAGE>

      10. Entire Agreement

This Agreement constitutes the entire agreement, and supersedes all prior
agreements and understandings, both written and oral, among the parties, with
respect to the subject matter hereto. This Agreement may only be amended,
modified or supplemented by a written agreement signed by all parties hereto.

      11. Severability

If any term or other provision of the Agreement is invalid, illegal or
unenforceable, all other provisions of this Agreement shall remain in full force
and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any
party.

      12. Waiver

No waiver by any party to this Agreement of any breach or default shall be
effective unless the same shall be in writing and signed. No waiver by any party
of any breach or default of any term or provisions of this Agreement shall be
construed to constitute a waiver of, or consent to, the present or future breach
or default of that or any other term or provision hereof.

      13. Successors and Assigns

This Agreement shall be binding upon the successors and assigns of the parties
hereto.

      14. Costs of Enforcement

In the event it becomes necessary for a party to take legal action to enforce
its rights under this Agreement, the party prevailing in such action shall be
entitled to an award including the costs and expenses (including reasonable
attorneys' fees) incurred in connection with such action.

      15. Arbitration of Disputes

Any disputes or litigation arising out of or related to this Agreement shall be
resolved pursuant to the arbitration laws of the state of Delaware.

                                       4
<PAGE>

      IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by
or on behalf of each of the parties hereto as of the date first above written.

DISPATCH MANAGEMENT SERVICES CORP.,
A Delaware Corporation

By:
    ------------------------------------
    Bruce Morgan, President

    ------------------------------------
    H. Steve Swink

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]